The Impact of Baseline Hemoglobin A1c Levels Prior to Initiation of Pump Therapy on Long-Term Metabolic Control

Pinhas‐Hamiel, Orit; Tzadok, Michal; Hirsh, Galit; Boyko, Valentina; Graph-Barel, Chana; Lerner‐Geva, Liat; Reichman, Brian

doi:10.1089/dia.2010.0006

Cited by 29 publications

(28 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 However, the most relevant finding of our study is that the interval onset-commencement is a linear predictor of MHbA1c throughout the follow-up: the shorter the interval, the lower the HbA1c level. Our results are in partial agreement with a previous observational study from Pinhas-Hamiel et al, 19 who demonstrated that lower HbA1c levels during a long-term follow-up (up to 7 years) are related to an interval onset-commencement of £1 year, but also other predictors, not useful in our model, were found: a baseline HbA1c level of £7.5% and a younger age at pump initiation. Another observational study from Shalitin et al 18 showed that a shorter diabetes duration is, together with other predictors, related to the achievement of the target HbA1c level.…”

Section: Discussionsupporting

confidence: 93%

The Effectiveness and Durability of an Early Insulin Pump Therapy in Children and Adolescents with Type 1 Diabetes Mellitus

BrancatoDavide¹,

FleresMattia²,

AielloVito³

et al. 2014

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Background: This study evaluated the predictors of effectiveness and durability of insulin pump therapy in children and adolescents who have initiated continuous subcutaneous insulin infusion (CSII) within 2 years after the diagnosis of type 1 diabetes mellitus (T1DM). Subjects and Methods: The charts of individuals with T1DM using insulin pumps who were treated at our center were reviewed, including subjects with age at onset of <22 years, interval between onset and insulin pump commencement (interval onset-commencement) of <2 years, use of pumps of >1 year, and use of glucose sensors for <4 weeks/year. The primary end point was the mean glycosylated hemoglobin (HbA1c) value (MHbA1c) throughout the follow-up. Results: From 684 patients treated with insulin pumps, 119 met the inclusion criteria, and 113 were selected for statistical analysis (60 females; age at diabetes onset, 8.9 -5.6 years [mean -SD]; follow-up, 4.0 -1.8 years; range, 1-8 years; baseline HbA1c, 9.3 -1.8%). Only the interval onset-commencement was a linear predictor of the MHbA1c (P = 0.01; R 2 = 0.089). A significant reduction of the mean yearly HbA1c from baseline throughout all the follow-up was observed (P < 0.001). Categorizing the sample into four quartiles on the basis of an increasing interval onset-commencement resulted in levels of MHbA1c significantly lower in the first and second quartiles in comparison with the fourth quartile (7.6 -0.8% and 7.8 -1.0%, respectively, versus 8.5 -0.8%; P < 0.001 and P = 0.004, respectively). Conclusions: The present study suggests that early pump commencement in children and adolescents with T1DM provides lower and more durable HbA1c values than a late commencement. It is possible that an early pump commencement could prolong the honeymoon phase, but we cannot confirm or exclude this hypothesis because the lack of data about C-peptide levels during the follow-up.

show abstract

Section: Discussionsupporting

confidence: 93%

The Effectiveness and Durability of an Early Insulin Pump Therapy in Children and Adolescents with Type 1 Diabetes Mellitus

BrancatoDavide¹,

FleresMattia²,

AielloVito³

et al. 2014

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…This 'Ucurve response' may explain why HbA 1c overall is not associated to more responders in our data. Orit Pinhas-Hamiel et al showed that the children with low HbA 1c prior to pump initiation actually increased their HbA 1c during seven years of follow-up [24]. This is consisting with our study where 55% of the population with low HbA 1c prior to pump initiation did not respond.…”

Section: Discussionsupporting

confidence: 89%

Characterization of metabolic responders on CSII treatment amongst children and adolescents in Denmark from 2007 to 2013

Ingeholm

Svensson

Olsen

et al. 2015

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

“…HbA1C was measured at each visit either by immunological in vitro assay (Tina-quant ® , Boehringer Mannheim Systems, Mannheim, Germany) or by a fi nger stick blood sample with the DCA 2000 + Analyzer (Bayer Inc., Tarrytown, NY) device following the manufacturer's guidelines. HbA1C levels of 2 methods correlated well (r = 0.88, P < 0.001) as described previously [ 21 ] . The study was approved by the Institutional Review Board of Maccabi Health Care Services and Sheba Medical Center.…”

supporting

confidence: 73%

Benefits of Continuous Subcutaneous Insulin Infusion (CSII) Therapy in Preschool Children

Levy‐Shraga

Lerner‐Geva

Modan‐Moses

et al. 2013

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

The Impact of Baseline Hemoglobin A1c Levels Prior to Initiation of Pump Therapy on Long-Term Metabolic Control

Abstract: Long-term response to pump treatment was dependent on baseline metabolic control. Early pump treatment had a significant long-term impact on metabolic control.

Cited by 29 publications

References 18 publications

The Effectiveness and Durability of an Early Insulin Pump Therapy in Children and Adolescents with Type 1 Diabetes Mellitus

The Effectiveness and Durability of an Early Insulin Pump Therapy in Children and Adolescents with Type 1 Diabetes Mellitus

Characterization of metabolic responders on CSII treatment amongst children and adolescents in Denmark from 2007 to 2013

Benefits of Continuous Subcutaneous Insulin Infusion (CSII) Therapy in Preschool Children

Contact Info

Product

Resources

About